Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury

Rantakari, Pia; Patten, Daniel; Valtonen, Joona; Karikoski, Marika; Gerke, Heidi; Dawes, Harriet; Laurila, Juha; Ohlmeier, Steffan; Elima, Kati; Hubscher, Stefan; Weston, Christopher; Jalkanen, Sirpa; Adams, David; Salmi, Marko; Shetty, Shishir

DOI:
10.1073/pnas.1604780113
10.1073/pnas.1604780113

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 29. Dec. 2018
Biological Sciences

Stabilin-1 expression defines a subset of macrophages which mediate tissue homeostasis and prevent fibrosis in chronic liver injury

Pia Rantakari¹*, Daniel A. Patten²*, Joona Valtonen¹, Marika Karikoski¹, Heidi Gerke¹, Harriet Dawes², Juha Laurila¹, Steffen Ohlmeier³, Kati Elima¹, Stefan G. Hubscher⁴, Christopher J. Weston², Sirpa Jalkanen¹, David H. Adams², Marko Salmi¹, Shishir Shetty²

1. MediCity Research Laboratory, and Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland.
2. National Institute for Health Research (NIHR) Biomedical Research Unit and Centre for Liver Research, Medical School, University of Birmingham, Birmingham, United Kingdom.
3. Proteomics Core Facility, Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
4. School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom

Corresponding Author- Shishir Shetty
Corresponding Address- Centre for Liver Research, 5th Floor, IBR, Medical School, University of Birmingham, UK, B15 2TT.
Phone: 44.0.121.415.8700
Fax: 44.0.121.415.8701
E-mail. s.shetty@bham.ac.uk

* These authors contributed equally to this work
Abstract

Macrophages are key regulators of fibrosis development and resolution. Elucidating the mechanisms by which they mediate this process is crucial for establishing their therapeutic potential. Here, we use experimental models of liver fibrosis to show that deficiency of the scavenger receptor, stabilin-1, exacerbates fibrosis and delays resolution during the recovery phase. We detected a subset of stabilin-1⁺ macrophages which were induced at sites of cellular injury close to the hepatic scar in mouse models of liver fibrosis and in human liver disease. Stabilin-1 deficiency abrogated malondialdehyde-LDL (MDA-LDL) uptake by hepatic macrophages and was associated with excess collagen III deposition. Mechanistically, the lack of stabilin-1 led to elevated intrahepatic levels of the pro-fibrogenic chemokine CCL3 and an increase in GFAP⁺ fibrogenic cells. Stabilin-1⁻⁻ macrophages demonstrated a pro-inflammatory phenotype during liver injury and the normal induction of Ly6Clo monocytes during resolution was absent in stabilin-1 knockouts leading to persistence of fibrosis. Human stabilin-1⁺ monocytes efficiently internalised MDA-LDL and this suppressed their ability to secrete CCL3 suggesting that loss of stabilin-1 removes a brake to CCL3 secretion. In support of this, studies with cell lineage specific knockouts revealed that stabilin-1 expression in myeloid cells is required for the induction of this novel subset of macrophages and that increased fibrosis occurs in their absence. This study demonstrates a new regulatory pathway in fibrogenesis in which a macrophage scavenger receptor protects against organ fibrosis by removing fibrogenic products of lipid peroxidation. Thus stabilin-1⁺ macrophages shape the tissue microenvironment during liver injury and healing.
**Significance Statement**

Organ fibrosis is a major cause of global morbidity and mortality. It is driven by chronic inflammation and associated oxidative stress with depletion of cellular antioxidant defenses. We demonstrate a novel mechanism in which the evolutionarily conserved receptor stabilin-1 on tissue-infiltrating macrophages provides a second-line defense to prevent tissue damage from oxidative stress. Stabilin-1+ monocytes take up malondialdehyde-LDL (MDA-LDL), a major product of oxidative lipid peroxidation, to form ceroid-laden macrophages. Through the uptake of MDA-LDL, stabilin-1 suppresses production of the pro-fibrogenic chemokine CCL3 and prevents excessive collagen deposition in experimental models of liver fibrosis. We propose that macrophage stabilin-1 is a critical defense against oxidative tissue damage and thereby maintains tissue homeostasis.

**Introduction**

Liver fibrosis is driven by extracellular matrix (ECM) deposition by activated myofibroblasts, the majority of which arise from the hepatic stellate cell (HSC) (1). The accumulation of an ECM rich in fibrillar collagens I and III, causes architectural distortion which leads to organ dysfunction and portal hypertension. Consequently, identifying pathways which regulate the deposition and resolution of fibrillar collagen is vital to developing new treatments for chronic liver disease. Products of oxidative stress, such as oxidised-low density lipoproteins (oxLDLs), can directly activate HSC to an ECM-producing state thereby driving fibrogenesis (2, 3). In addition to HSCs, other non-parenchymal cells, contribute to the regulation of liver fibrosis. Hepatic sinusoidal endothelial cells (HSEC), which lie in close proximity to HSCs,
play an important role in maintaining HSC quiescence (4), and macrophages play a critical role in fibrosis progression, tissue remodelling and resolution (5).

Stabilin-1, also known as CLEVER-1 (gene name Stab1), is a highly conserved transmembrane glycoprotein that is expressed by sinusoidal endothelium, and sub-populations of macrophages (6). Previous studies have demonstrated multiple stabilin-1 ligands including oxLDL (7), the ECM glycoprotein osteonectin (8) and placental lactogen (9) suggesting that stabilin-1 functions as a homeostatic scavenger receptor. We have previously reported stabilin-1 expression by HSEC, but not by resident liver macrophages (known as Kupffer cells), in normal human liver (10). Our observation of increased expression in a range of chronic inflammatory liver diseases led us to study whether stabilin-1 contributes to the progression of chronic liver disease and fibrogenesis.

Results

Stabilin-1 deficiency exacerbates liver fibrosis

To investigate the functional role of stabilin-1 in liver injury and fibrosis we used two mouse models. In carbon tetrachloride (CCl₄)-induced chronic liver injury a fibrogenic phase is followed by a spontaneous resolution phase (11) and in mice fed a methionine choline deficient (MCD) diet hepatic steatosis is followed by inflammation and early fibrosis (12).

Consistent with previous reports in stabilin-1⁻/⁻ mice, sirius red positive fibres consistent with increased fibrogenesis were seen within the liver parenchyma which was otherwise normal (Fig.1A,B) (13). Following CCl₄ administration, stabilin-1⁻/⁻ mice developed a marked increase in hepatic scar formation compared with WT mice with features of bridging fibrosis (Fig.1A,B) and increased sirius red staining (SI Appendix Fig.S1A). Greater activation of fibrogenic pathways in stabilin-1⁻/⁻ mice was confirmed by significantly increased accumulation of collagen I and III (Fig.1C,D, SI Appendix Fig.S1B,C). In order to study
the number and activation of fibrogenic cells at baseline and injury we compared the expression of glial fibrillary acidic protein (GFAP) as a constitutive marker of stellate cells to alpha smooth muscle actin (αSMA) and matrix metalloproteinase-2 (MMP-2) as markers of activated myofibroblasts (14, 15). At baseline and throughout injury and resolution we detected increased GFAP expression in livers of stabilin-1−/− mice (Fig.1E-H). In contrast αSMA and MMP-2 expression was significantly higher only during injury (Fig.1E-H, SI Appendix Fig.S1D,E) compared to WT mice.

The role of stabilin-1 in the resolution of fibrosis was studied in mice during recovery after CCl4 injury. After four weeks of recovery, we noted persistent bridging fibrosis and increased collagen I and III transcription in stabilin-1−/− mice when compared to WT mice (Fig.1I,J). Hydroxyproline quantification demonstrated an increase in collagen content in stabilin-1−/− mice at baseline comparable to that seen in WT mice after CCl4 administration (Fig.1K). After four weeks of resolution, the hydroxyproline had reduced in WT mice but increased further in stabilin-1−/− mice (Fig.1K). We also noted that stabilin-1−/− mice demonstrated significantly increased ALT levels during liver injury (Fig.1L). To assess if elevated ALT levels were due to increased hepatocyte death or inefficient scavenging we co-stained for ALT and F4/80 and assessed markers of cell death. We found increased co-expression of ALT and F4/80 in WT mice compared to stabilin-1−/− mice, but no significant difference in levels of apoptosis and autophagy (SI Appendix Fig. S2 A-I). Histological assessment demonstrated minimal necrosis with no difference between WT and stabilin-1−/− mice at baseline or after 8 weeks of carbon tetrachloride (SI Appendix Fig. S2 J). These findings suggest inefficient scavenging in stabilin-1−/− mice rather than increased cellular death.

We also detected histologically more severe scarring in stabilin-1−/− MCD diet fed mice and significantly increased hydroxyproline levels compared to WT MCD diet fed mice, as well as,
higher, but not statistically significant, ALT levels (SI Appendix Fig. S3 A-E). Collectively these data show that in vivo there is an increased baseline fibrogenic response in stabilin-1−/− mice, which is due to increased numbers of fibrogenic cells. Fibrosis and scarring are enhanced upon injury, and the resolution phase is impaired in the absence of stabilin-1.

**Injury-dependent induction of stabilin-1 in hepatic macrophages**

We proceeded to study the cellular expression of stabilin-1 in normal and injured murine livers. In uninjured WT mice, stabilin-1 was restricted to CD31-positive sinusoidal endothelial cells and was absent from F4/80-positive Kupffer cells (SI Appendix Fig. S4A,B). In response to liver injury from either CCl4 or MCD diet we detected a subset of stabilin-1+ F4/80+ intrahepatic macrophages (SI Appendix Fig. S4C, S5A). Using αSMA as a cell lineage marker, we clearly demonstrated that myofibroblasts, which play a central role in liver fibrosis, do not express stabilin-1 during liver injury (SI appendix Fig. S4D, S5B).

Analysis of chronic human liver disease demonstrated that CD31-positive sinusoidal endothelial cells expressed stabilin-1 whereas CD68-positive Kupffer cells within the sinusoids did not (SI Appendix Fig. S4E,F). In contrast, stabilin-1+ macrophages were readily detected within the fibrous septa associated with the hepatic scar (SI Appendix Fig. S4G). Stabilin-1 was not detected on αSMA-positive myofibroblasts (SI Appendix Fig. S4H). These studies demonstrate for the first time an intrahepatic subpopulation of stabilin-1+ macrophages in liver injury.

**Stabilin-1 deficiency leads to a reduction of ceroid macrophages in liver injury.**

The presence of a population of stabilin-1+ macrophages in liver injury and previous findings that macrophages are critical to the development of fibrosis (16), led us to investigate whether an alteration in macrophage distribution or function contributes to the increased fibrosis in stabilin-1−/− mice. Intrahepatic macrophage distribution and peripheral
blood monocyte numbers were comparable between uninjured WT and stabilin-1−/− mice (Fig.2A,B, SI Appendix Fig S9A). After CCl₄ injury, WT mice demonstrated prominent aggregates of macrophages, which were not seen in the stabilin-1−/− animals (Fig.2A-C). These macrophage aggregates resembled ceroid-laden macrophages. Ceroid-laden macrophages contain lipid-like pigment deposits and have been previously described in experimental liver fibrosis but their pathological significance is unknown (17, 18).

We hypothesized that stabilin-1 deficiency was associated with a reduction in ceroid-laden macrophage formation during liver injury and fibrosis. To test this hypothesis, we used periodic acid-schiff diastase (PAS-D) staining to detect cytoplasmic ceroid accumulation. This confirmed the presence of large ceroid macrophages in WT mice (Fig.2D) that were largely absent in stabilin-1−/− animals (Fig.2D). Interestingly, PAS-D also stains the fibrous scar and in the stabilin-1−/− mice the absence of ceroid-laden macrophages was associated with prominent fibrosis (Fig.2D).

MDA is the most abundant aldehyde produced by lipid peroxidation and is highly reactive leading to the formation of MDA-modified LDL. This product of oxidative stress is taken up by macrophages and contributes to cytoplasmic ceroid accumulation (19). In WT mice, prominent MDA-positive cells were clearly visible (Fig.2E), whereas minimal staining was detected in stabilin-1−/− mice (Fig.2E,F).

A further well established property of ceroid accumulation is that the pigment, including MDA adducts, is autofluorescent (20). We identified prominent autofluorescent F4/80+ aggregates in WT mice which were greatly reduced in stabilin-1−/− mice in both CCl₄- and MCD diet-induced liver injury (Fig.2G,H). We then showed that F4/80+ ceroid-laden macrophages in experimental liver injury in WT mice co-express stabilin-1 (Fig.2I).

We used a thiobarbituric acid reactive substances (TBARS) assay to detect serum MDA and found similar levels in WT and stabilin-1−/− mice after CCl₄ injury and MCD diet
suggesting that production of MDA is not reduced in stabilin-1 deficiency (Fig.2J).

Proteomic analysis of baseline serum samples demonstrated increased levels of several proteins in the serum of stabilin-1−/− mice compared to WT mice (SI Appendix Table S1) several of which are related to oxidative stress. However we did not detect increased circulatory levels of pro-inflammatory or pro-fibrogenic cytokines such as TGFβ, PDGF A and B, in keeping with previous studies (13).

Our findings prompted us to study the distribution of ceroid-laden macrophages in relation to sites and stage of fibrosis. We detected ceroid-laden macrophages along the hepatic scar in WT mice (Fig.3A) whereas in stabilin-1 deficient animals, the absence of ceroid macrophages was associated with a dense network of collagen III in the hepatic scar (Fig.3B). Further analysis of livers after 4 weeks resolution demonstrated the persistence of ceroid-laden macrophages in close proximity to residual hepatic scar in WT mice (Fig.3C). In contrast, ceroid-laden macrophages were not seen in stabilin-1−/− mice in which extensive collagen-rich scars persisted after 4 weeks of resolution (Fig.3D). Thus, collectively our data suggest that stabilin-1 on macrophages protects against liver fibrosis by taking up fibrogenic modified lipids.

**Stabilin-1 deficiency is associated with excess CCL3 production in liver tissue and stabilin-1 suppresses CCL3 expression in macrophages.**

To identify specific mediators of fibrogenesis in stabilin-1 deficiency, we used RNA-seq to compare the gene expression profile of liver tissue from WT and stabilin-1−/− mice. A number of genes showed increased expression in stabilin-1−/− mice (SI Appendix Table S2) but the only established fibrogenic mediator which was increased was the chemokine CCL3 (21, 22). We validated our findings with qPCR of liver tissue and critically demonstrated that CCL3 was persistently elevated after four weeks of resolution in stabilin-1−/− mice.
In support of these findings we detected increased CCL3 protein in stabilin-1\(^+\) mice which colocalised with hepatic macrophages (Fig. 4B-D).

We investigated whether the pro-fibrogenic phenotype in livers of stabilin-1\(^+\) mice was linked to ox-LDL uptake to form ceroid-laden macrophages. We initially confirmed the presence of autofluorescent stabilin-1\(^+\) ceroid-laden macrophages in livers from patients with chronic liver diseases (SI Appendix Fig. S6A,B).

As MDA-LDL is one of the most abundant products of lipid peroxidation and contributes to ceroid formation (23), we investigated whether stabilin-1 on human macrophages is involved in its uptake and degradation. We isolated monocytes from human peripheral blood and stimulated their stabilin-1 expression \textit{in vitro} (24). After 2 hours of MDA-LDL incubation we were able to detect intracellular deposits of MDA-LDL completely colocalised with stabilin-1 (SI Appendix Fig. S7A). Uptake of MDA-LDL was minimal in unstimulated monocytes which had low expression of stabilin-1 (SI Appendix Fig. S7B). A function blocking antibody to stabilin-1 led to the internalisation of stabilin-1 thereby inhibiting MDA-LDL uptake (Fig. 5A,B). We also linked the scavenging function of stabilin-1 positive macrophages to CCL3 expression by demonstrating a significant reduction in macrophage CCL3 transcription after MDA-LDL uptake compared to control (Fig. 5C). We could reverse this effect using the function blocking antibody against stabilin-1 (Fig. 5D).

These results suggest that stabilin-1 expression is critical for the uptake of MDA-LDL by macrophages, a process which also modulates macrophage-derived CCL3 secretion.

**Stabilin-1 deficiency is associated with a pro-inflammatory hepatic macrophage phenotype.**

To assess how stabilin-1 deficiency influenced macrophage phenotype we sorted macrophages from CCl\(_4\) treated livers. Analysis of WT hepatic macrophage populations
during liver injury demonstrated higher transcript expression of stabilin-1 in F4/80^{hi}/CD11b^{lo} compared to the F4/80^{lo}/CD11b^{hi} population (SI Appendix Fig S8A). The loss of stabilin-1 led to higher expression of M1 markers CCL3 and TNFα in both F4/80^{hi}/CD11b^{lo} and F4/80^{lo}/CD11b^{hi} subsets. M2 marker MMP-9 was also elevated but Arginase-1 was reduced in the F4/80^{hi}/CD11b^{lo} subset (SI Appendix Fig. S8B-E). This is in keeping with previous studies where defining macrophages through their polarisation to classical M1 or M2 macrophages is unreliable in liver injury as M1/M2 markers can be expressed simultaneously by liver macrophages (25).

Ramachandran et al. demonstrated that the CD11b^{hi}Ly6C^{lo} monocyte-derived macrophage population increases significantly during fibrosis resolution and functions as the ‘restorative’ macrophage (25) leading us to compare populations of ‘pro-fibrotic’ CD11b^{hi}Ly6C^{hi} and ‘restorative’ CD11b^{hi} Ly6C^{lo} macrophages. Liver injury in both WT and stabilin-1^{-/-} mice resulted in a predominance of Ly6C^{hi} macrophages in the liver (SI Appendix Fig. S8F,G). During resolution there was a shift towards Ly6C^{lo} macrophages in the WT group which was not seen in the stabilin-1^{-/-} mice (SI Appendix Fig. S8H). Intrahepatic lymphocyte populations did not differ between WT and stabilin-1^{-/-} mice after the injury or during resolution (SI Appendix Fig. S9B-K). Collectively, these results demonstrate that the profibrogenic response in stabilin-1 deficiency is associated with a pro-inflammatory macrophage phenotype during injury.

**Deletion of stabilin-1 in myeloid cells is associated with a loss of ceroid-laden macrophages and exacerbated fibrosis.**

The preceding results suggest that stabilin-1 protects the liver from fibrosis by allowing macrophages to take up and remove pro-fibrogenic lipid peroxidation products and at the same time suppressing CCL3 production. To test this hypothesis *in vivo* we used Tie-2 Cre
and Lys2 Cre strains to generate cell-selective knockouts. We have previously confirmed their selectivity and efficiency in knocking down stabilin-1 (26). We have shown that in our Tie-2 Cre model stabilin-1 is absent from endothelium (ENDO stab-1⁻⁺) but macrophage expression is maintained. In our Lys2 Cre model stabilin-1 is absent from the myeloid population (MACRO stab-1⁻⁺). In practice this model is selective for macrophages, since neutrophils do not express stabilin-1 and therefore are unaffected by this knockout. We confirmed this specificity in the livers of our cell selective strains at baseline and during liver injury (SI Appendix Fig. S10A,B).

Fibrosis in ENDO stab-1⁻⁺ mice was comparable to WT mice in both CCl₄ liver injury and MCD diet (SI Appendix Fig. S11A-C), whereas fibrogenesis was increased in MACRO stab-1⁻⁺ animals (Fig.6A,B) with significantly more accumulation of collagen III associated with increased αSMA staining in MACRO stab-1⁻⁺ mice versus WT after CCl₄ injury (Fig.6C-F). Fibrosis resolution was delayed in the MACRO stab-1⁻⁺ animals as demonstrated by persistently elevated transcript levels of αSMA and increased hydroxyproline staining and critically for our hypothesis we found persistent elevation of CCL3 compared to WT animals (Fig.6G-I) and increased serum ALT levels in response to CCl₄ as seen in the full knockout (Fig.6J). We also detected significantly elevated hydroxyproline content in MACRO stab-1⁻⁺ mice compared to WT mice after MCD diet (SI Appendix Fig.S11D). Thus the increased fibrosis in response to liver injury seen in the absence of stabilin-1 is predominantly mediated through stabilin-1 expressing macrophages.

There were no detectable differences in the numbers of ceroid-laden macrophages in the livers of WT and ENDO stab-1⁻⁺ mice (SI Appendix Fig. S11E,F). In contrast, very few ceroid-laden macrophages were seen in the livers of CCl₄ treated MACRO stab-1⁻⁺ animals (SI Appendix Fig. S11E,F). To further confirm the role of macrophage stabilin-1 in fibrosis resolution we undertook experiments similar in design to those described by


Ramachandran et al. (25). This consisted of a 4 week model of CCl₄ liver injury performed in MACRO stab-1⁻/⁻ and WT mice followed by adoptive transfer of wild type myeloid cell elements or vehicle control at 24 and 72 hours after the final injection of CCl₄ followed by an analysis of fibrogenesis at 120 hours. Transcription of fibrogenic markers and collagen III expression in liver tissue showed no differences between WT mice receiving myeloid cells or vehicle without cells (SI Appendix Fig S12A,D,F), whereas in the MACRO stab-1⁻/⁻ there was a trend of reduced transcription in nearly all fibrogenic markers in mice receiving wild type myeloid cells (SI Appendix Fig. S12B). We confirmed the presence of adoptively transferred Dsred⁺ myeloid cells within liver tissue at sites of collagen deposition (SI Appendix Fig. S12C). Finally, we demonstrated a significant reduction in hepatic collagen III expression in MACRO stabilin-1⁻/⁻ mice receiving wild type myeloid cells compared to vehicle control (SI Appendix Fig. 12E,F).

Discussion

This study reports a novel mechanism which involves a subset of stabilin-1⁺ macrophages found in both experimental and human liver injury which play a critical role in protecting against excessive fibrosis in response to oxidative stress. Stabilin-1 deficiency led to an increase in hepatic CCL3 associated with the recruitment of GFAP⁺ fibroblasts and an increase in baseline hepatic fibrosis. Using cell-specific knockout animals we were able to show that stabilin-1 mediates its effects by enabling macrophages to take up and clear fibrogenic oxidised lipids generated in response to liver injury. Stabilin-1 deficiency was associated with a marked reduction of ceroid-laden macrophages during liver injury. Ceroid-laden macrophages are a well recognised pathological feature of liver injury but, to our knowledge, their contribution to liver fibrosis is unknown. Ceroid contains modified lipoproteins (such as MDA-LDL) which are generated as a consequence of chronic
oxidative stress. We found in both humans and mice that they are derived from a subset of macrophages, that upregulate stabilin-1. The expression of stabilin-1 allows macrophages to take up and clear modified LDLs and in addition we show that this uptake suppresses the secretion of the pro-fibrogenic chemokine CCL3 resulting in reduced fibrosis and the promotion of scar resolution. The highest levels of stabilin-1 were detected in the F4/80$^{hi}$ CD11b$^{lo}$ population suggesting that tissue resident macrophages may upregulate stabilin-1 during liver injury. Interestingly, stabilin-1 deficiency was associated with an inflammatory phenotype in both infiltrating monocytes and mature tissue resident macrophages. The therapeutic potential of stabilin-1$^+$ macrophages was demonstrated by our finding that the adoptive transfer of wild type myeloid cells can promote resolution of fibrosis in stabilin-1 deficiency. These results suggest that macrophages which are stimulated or engineered to express high levels of stabilin-1 could be a potential cell therapy in fibrotic liver disease. In addition to its potential role in liver disease we suggest that stabilin-1 plays a role in tissue homeostasis by removing local products of low level oxidative stress. This explains why increased fibrosis is seen in stabilin-1 deficient mice even in the absence of exogenous injury. The liver is constantly exposed to bacterial products and xenobiotics from both the portal and systemic circulation and under normal conditions stabilin-1 on endothelium as well as on macrophages may allow the rapid removal of products of oxidative stress thereby preventing low level continuous injury and scarring. Whereas in response to liver injury, protection and resolution requires the involvement of stabilin-1$^+$ macrophages. These findings describe a novel mechanism involved in the regulation of tissue fibrosis that allows efficient wound healing without destructive scarring in response to liver injury.

Methods

Animals
Stabilin-1 knockout mice and cell-specific mice were generated as previously described (26). CAG-Dsred*MST\textsuperscript{1Nagy/J} (stock 005441) were from the Jackson Laboratory. All animal studies were done in adherence with the rules and regulations of The Finnish Act on Animal Experimentation (62/2006), and accepted by the local Committee for Animal Experimentation (Animal licence number 5587/04.10.07/2014).

**Liver injury models**

*Carbon tetrachloride (CCl\textsubscript{4}) injury model*

8-week-old mice were injected twice weekly for 8 weeks with either CCl\textsubscript{4} (1.0 ml/kg CCl\textsubscript{4} diluted 1:3 in mineral oil, Sigma-Aldrich) or a mineral oil vehicle control. Animals were sacrificed 72 h after the final dose of CCl\textsubscript{4} (27) or after a 4-week recovery period.

*Methionine Choline Deficient (MCD) Diet*

Mice were fed an MCD diet (Harlan laboratories TD90262) for 6 weeks ad libitum. Control animals received normal chow for 6 weeks (27).

**Human tissue**

Tissue and blood samples from patients were obtained with written informed consent and with local ethics committee approval (LREC reference 06/Q2702/61 South Birmingham, Birmingham, UK and 04/Q2708/41 South Birmingham, Birmingham, UK).

Statistical analysis, see SI Appendix Supplementary methods.

**Acknowledgements**

We are grateful to our clinical colleagues and patient donors for the provision of blood and tissue samples. SS was funded by a Wellcome Trust Intermediate Clinical Fellowship.
This work was funded by the Finnish Academy and the Sigrid Juselius Foundation.

This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

References


Figure Legends

Figure 1

Stabilin-1 deficiency exacerbates fibrosis after CCl₄ liver injury. Wild-type (WT) and stabilin-1-deficient (stabilin-1⁻/⁻) mice were subjected to CCl₄-induced liver injury: control (Oil); 8 week CCl₄ injury (CCl₄) and 4 week resolution after the CCl₄ injury (Res). (A,B) Sirius red stainings in livers (n=4-5 in each group). (C-H) Collagen I, Collagen III
immunostainings stainings and GFAP/αSMA co-immunostainings and quantifications of liver sections (n=3-5 in each group). (I) Sirius red staining from livers after resolution. (J) mRNA expression of Collagen I and Collagen III in livers. (K) Hydroxyproline determinations in liver samples and (L) serum alanine transaminase (ALT) levels. (for J-L n=5-6 mice in each group). Statistical significance was determined by unpaired t-test (G,H,J) and 1-way ANOVA analysis, with a Tukey’s post-hoc multiple comparison test (K, L). * P<0.05, ** P<0.005, ***P<0.001, ****P<0.0005. Bars 200µm (A-D, I) Bars 50 µm (E, F)

**Figure 2**

Stabilin-1 deficiency is associated with a reduction of ceroid-laden macrophages during liver injury. (A,B) Staining of livers for F4/80 from WT and stabilin-1−/− mice in oil controls and CCl4 injury. Arrows indicate aggregates of F4/80+ cells. (C) Quantification of F4/80 positive area staining in WT and stabilin-1−/− mice in oil controls and CCl4 injury. (D) Periodic acid Schiff-diastase (PAS-D) staining of livers from WT and stabilin-1−/− mice after CCl4 injury (black arrows highlight PAS-D positive cells and white arrows highlight areas of increased scar formation. (E) Staining of livers for Malondialdehyde (MDA) from WT and stabilin-1−/− mice after CCl4 injury (F) Quantification of MDA positive area staining in WT and stabilin-1−/− mice after CCl4 injury. (n=3-4 mice in each group) Representative high magnification fields in black box areas. (G) Autofluorescent ceroid aggregates (red) co-stained with F4/80 (green) in WT and stabilin-1−/− mice after CCl4 injury. (H) Quantification of ceroid staining within F4/80+ cells in livers from WT and stabilin-1−/− mice after CCl4 injury and MCD diet. (n=5 mice in each group). (I) Immunofluorescent staining of livers from WT mice after CCl4 injury double stained for F4/80 (green), stabilin-1 (orange) and autofluorescent ceroid (red). (J) Measurement of serum MDA levels using TBARS assay in WT and stabilin-1−/− mice after CCl4 injury and MCD diet-induced injury (n=4 mice in each
group). Statistical significance was determined by unpaired t-test (C,F,H,J) * P<0.05, ** P<0.005, ***P<0.001. Bars 100 µm (A,B), 200 µm (D,E), 50 µm (G), 10 µm (I).

Figure 3
Loss of ceroid-laden macrophages is associated with exacerbation of hepatic scarring.

(A,B) Immunofluorescent staining of WT and stabilin-1−/− mice after CCl₄ injury and (C,D) 4 weeks resolution for F4/80⁺ cells (green) and Collagen III (red). Right hand panels are magnification of inset boxes in left hand panels (arrows highlight ceroid-laden macrophages). Bars 200 µm (A-D).

Figure 4
Stabilin-1 deficiency is associated with increased intrahepatic CCL3. Wild-type (WT) and stabilin-1-deficient (stab-1−/−) mice were subjected to CCl₄-induced liver injury: control (Oil); 8 week CCl₄ injury (CCl₄) and 4 week resolution after the CCl₄ injury (Res). (A) mRNA expression of CCL3 in livers (n=5-7 mice in each group). (B) Immunofluorescent staining of WT and stabilin-1−/− mice in control (Oil) livers of F4/80⁺ cells (red) and CCL3 (green) and (C) quantification of CCL3 staining (n=3 in each group for B,C). (D) High magnification image of co-staining for F4/80⁺ cells (red) and CCL3 (green) from stabilin-1-deficient (stab-1−/−) liver. Statistical significance was determined by unpaired t-test (A,C) *P<0.05, ** P<0.005, Bars 50 µm (B), 5 µm (D).

Figure 5
Stabilin-1 suppresses CCL3 expression during Malondialdehyde-LDL uptake by macrophages.
(A) Immunofluorescent staining of IL-4/Dex cultured human monocytes pre-treated with isotype control and or (B) Stabilin-1 function blocking antibody (3-372) followed by incubation with MDA-LDL (10 µg/ml) for 2 h. Representative images from three separate cell isolates. (C) Comparison of mRNA expression of CCL3 in IL-4/Dex cultured human monocytes (control) and those exposed to MDA-LDL for 24h. (D) Comparison of mRNA expression of CCL3 in IL-4/Dex cultured human monocytes exposed to MDA-LDL for 24h, pre incubated with IgG1 antibody (control; 10 µg/ml) or 3-372 antibody (Stab-1 blocking antibody; 10 µg/ml) (n=3 independent experiments). Statistical significance was determined by a paired t-test. *P<0.05, ***P<0.005. Bar 10 µm (A,B),

Figure 6

Stabilin-1 deficiency on macrophages leads to increased ECM deposition. Wild-type (WT) and macrophage stabilin-1-deficient (MACRO stab-1−/−) mice were subjected to (A-H) CCl₄-induced liver injury: control (Oil); 8 week CCl₄ injury (CCl₄) and 4 week resolution after the CCl₄ injury (Res). (A,B) Sirius red stainings in livers. (C-F) Collagen I, Collagen III and αSMA immunostainings and quantifications of liver sections. (G) mRNA expression of αSMA and CCL3 in livers, (for A-G n=4-6 mice in each group). (H) Hydroxyproline determinations in liver samples (n=5-6 mice in each group) and serum alanine transaminase (ALT) levels (n=4-5 mice in each group). Statistical significance was determined by unpaired t-test (E) and 1-way ANOVA analysis, with a Tukey’s post-hoc multiple comparison test (G, H). * P<0.05, ***P<0.001. Bars 200 µm (A-D). Bars 50 µm (F).
Figure 2

A. Oil vs CCl4 in WT and stabilin-1/-. 
B. Oil vs CCl4 in stabilin-1/-. 
C. Area-% comparison of oil and CCl4 in WT and stabilin-1/-. 
D. CCl4 treated samples with black arrows indicating differences. 
E. MDA in WT and stabilin-1/-. 
F. Area-% comparison of MDA in WT and stabilin-1/-. 
G. F4/80 Ceroid in WT and stabilin-1/-. 
H. Ceroid Macrophages area-% comparison between CCl4 and MCD diet. 
I. Overlay of F4/80 Ceroid and stab-1 Ceroid in WT. 
J. Serum MDA levels in CCl4 and MCD diet.
Figure 3

A) CCl4

WT  F480 Collagen III

B) CCl4

stabilin-1/-

F480 Collagen III

C) Resolution

WT  F480 Collagen III

D) Resolution

stabilin-1/-

F480 Collagen III
Figure 4

A. CCL3

<table>
<thead>
<tr>
<th></th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oil</td>
<td>**</td>
</tr>
<tr>
<td>ccl4</td>
<td>2.5</td>
</tr>
<tr>
<td>res</td>
<td>1.5</td>
</tr>
</tbody>
</table>

B. WT vs stabilin-1/-

CCL3 staining in WT and stabilin-1/-

C. CCL3

<table>
<thead>
<tr>
<th></th>
<th>area, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oil</td>
<td>**</td>
</tr>
</tbody>
</table>

D. stabilin-1/-

CCL3 staining in stabilin-1/-
Figure 6

A. Oil vs CCI4
B. MACRO stab 1-1/

C. Coll I vs Coll III
D. MACRO stab 1-1/

E. Collagen I and III area percentage

F. WT vs CCI4
G. αSMA WT vs macro KO
H. CCL3 WT vs macro KO
I. Hydroxyproline WT vs macro KO
J. ALT WT vs macro KO

574